MCRB May 2024 1.000 call
| Previous close | 0.2500 |
| Open | 0.3000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 1.00 |
| Expiry date | 2024-05-17 |
| Day's range | 0.1500 - 0.3200 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.4k |
- Business Wire
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., May 06, 2024--Seres Therapeutics, Inc. (Nasdaq: MCRB) ("Seres" or the "Company"), a leading microbiome therapeutics company, today announced that on May 1, 2024, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 9,367 shares of its common stock to two new employees, consisting of stock options to purchase 6,244 shares of common stock and restricted stock units ("RSUs") covering 3,123 shares of its common
- Business Wire
Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024
CAMBRIDGE, Mass., May 06, 2024--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on May 8, 2024 at 8:30 a.m. ET to discuss first quarter 2024 financial results and provide business updates.
- Business Wire
Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT
CAMBRIDGE, Mass., April 09, 2024--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that enrollment is complete in the placebo-controlled Cohort 2 of its Phase 1b trial of SER-155 in patients who received Allogeneic Hematopoietic Stem Cell Transplantation (Allo HSCT). SER-155 is an orally administered, consortium of bacteria, cultivated from cell banks and designed to reduce the incidence and severity of enteric-derived infections and resulting b
